Quattro Advisors’s Biogen BIIB Stock Holding History

Quattro Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-52	Closed	-$9.15K	–	107
2025 Q4	$9.15K	Buy	+52	New	+$8.49K	0.01%	247

Other funds holding BIIB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Quattro Advisors's BIIB Position: Q1 2026 in Review

Quattro Advisors sold out of Biogen (BIIB) in Q1 2026, closing a stake of 52 shares — an estimated $9.15K sold.

Quattro Advisors first reported a position in BIIB in Q4 2025 and held it in 1 quarter. The position peaked at $9.15K in Q4 2025. 1,012 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

Quattro Advisors reported no remaining Biogen position as of Q1 2026 after selling out during the quarter.
Quattro Advisors sold 52 Biogen shares in Q1 2026, an estimated $9.15K.
Quattro Advisors first reported a position in Biogen in Q4 2025 and held it in 1 quarter.
Quattro Advisors's Biogen position peaked at $9.15K in Q4 2025.
1,012 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Quattro Advisors's 13F filing for Q1 2026, filed 15 May 2026.